2022H1: Top 10 Best-Selling Drugs in the World

With the release of the semi-annual reports of major pharmaceuticalcompanies in 2022, the TOP10 list of the world's best-selling drugs has becomeclear. The new crown mRNA vaccines of Pfizer/BioNtech and Moderna ranked firstand second, with sales of $22.075 billion and $10.456 billion respectively. Thesales of "Drug King" Humira was US$10.099 billion, a slight decline.Keytruda's sales were US$10.061 billion, which will surpass Humira for thefirst time this year, and the new "Drug King" has landed. Pfizer’s new crown oraldrug Paxlovid had sales of $9.585 billion in the first half of the year and isexpected to sell $22 billion for the full year. Bristol-Myers Squibb'slenalidomide sales of US$5.298 billion began to decline rapidly due to theimpact of generic drugs. Johnson & Johnson's IL-12/IL-23 antibody Stelarahas sales of US$4.887 billion, which may exceed US$10 billion for the firsttime this year. Regeneron's Eylea sales were $4.877 billion, and Gilead's newHIV drug Biktarvy had sales of $4.707 billion.

Bristol-Myers Squibb’s PD-1 antibody Opdivo has sales of $4.496 billion, and Merck’s new crown oraldrug Lagevrio has sales of $4.424 billion. Johnson & Johnson/AbbVie's BTKinhibitor Imbruvica saw a slight decline in sales of $4.326 billion.Regeneron/Sanofi’s IL-4R antibody sales were US$3.902 billion, and the indications arestill expanding. The target of US$10 billion has been clearly seen, and it hasbecome another milestone product in the field of autoimmunity. Johnson &Johnson's CD38 antibody Darzalex has sales of US$3.842 billion, stillmaintaining rapid growth, and the share of macromolecules in the multiplemyeloma market is increasing. Merck's cervical cancer vaccine Gardasil hasgrown rapidly, with sales of US$3.133 billion in the first half of the year,especially the rapid expansion of the Chinese market.

The sales of Xarelto, semaglutide, dulaglutide, and Trikafta have notbeen disclosed, and they are expected to rank in the top 15.